Premaitha reveals 100% accuracy

AN independent study into Premaitha Health’s newly-launched IONA non-invasive prenatal test (NIPT) has revealed 100% accuracy. The Manchester-based company’s NIPT test detects the risk of a fetus being by Down’s Syndrome and other serious genetic conditions such at Patau’s Syndrome and and Edwards Syndrome and is carried out by analysing fetal DNA from a sample of maternal blood.

The result of the study undertaken by a team led by Professor Kypros Nicolaides with Dr Liona Poon as the lead author at the Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, has been published in the Journal of Ultrasound in Obstetrics and Gynaecology.

Prof Nicolaides said: “I am very impressed by the accuracy of the IONA test.”

Dr Poon said: “I hope the new technology used in the IONA test will allow easy implementation of cfDNA testing in the screening for major fetal aneuploidies.”

Premaitha chief medical officer Dr William Denman, said: “These results confirm what our customers have already reported; that the IONA test is a highly accurate, robust and simple screen for Down’s Syndrome and other serious genetic conditions.

“It is a great endorsement of the test that Prof Nicolaides and his team have chosen to verify it. We believe this should encourage broader and appropriate uptake of NIPT, benefiting pregnant women and their families through the increased accuracy, especially the reduction in false positive results that the IONA test provides.”

See the article in full at


Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.